期刊文献+

沙培林雾化吸入联合NP方案对晚期非小细胞肺癌的疗效观察及T细胞亚群的影响 被引量:4

The Effect of Sapylin Inhalation Combined with NP Regimen for the Treatment of Advanced Non-small Cell Lung Cancer and T Lymphocyte Subsets
下载PDF
导出
摘要 目的:观察沙培林雾化吸入联合NP方案治疗晚期非小细胞肺癌的临床疗效及其对T细胞亚群的影响。方法:选取本院收治的晚期非小细胞肺癌患者68例,随机分为沙培林雾化吸入联合NP方案组(O-NP组)及单纯NP方案组(NP组),每组各34例,比较两组治疗后的临床疗效及T细胞亚群水平。结果:O-NP组的临床疗效明显优于NP组,两组比较差异有统计学意义(P<0.05);O-NP组治疗后T细胞亚群水平明显优于治疗前,也明显优于NP组,差异均有统计学意义(P<0.05)。结论:沙培林雾化吸入联合NP方案治疗晚期非小细胞肺癌的疗效显著,可有效改善患者免疫功能,值得临床推广应用。 Objective: To observe the clinical effect of Sapylin inhalation combined with NP regimen for the treatment of advanced non-small cell lung cancer and its effects on the T lymphocyte subsets.Method : 68 cases of advanced non-small cell lung cancer in our hospital were selected, they were randomly divided into inhalation combined with NP regimen group ( O-NP group ) and NP regimen alone group ( NP group ), 34 cases in each group. The clinical efficacy of the two groups after treatment and the level of T cells subsets before and after treatment were compared.Result: The clinical effect of O-NP group was significantly better than that of NP group, the difference was statistically significant ( P〈0.05 ) .In O-NP group, the T cells subgroup level after treatment was significantly better than before, and it was also significantly better than that in NP group, the differences were statistically significant ( P〈0.05 ) . Conclusion: Sapylin inhalation combined with NP regimen for the treatment of advanced non-small cell lung cancer is effective, can effectively improve the immune function, it is worthy of clinical application.
作者 谢传华
出处 《中国医学创新》 CAS 2015年第28期38-40,共3页 Medical Innovation of China
关键词 沙培林 雾化吸入 NP方案 晚期 非小细胞肺癌 T细胞亚群 Sapylin Inhalation NP regimen Advanced Non-small cell lung cancer T cell subsets
  • 引文网络
  • 相关文献

参考文献12

二级参考文献37

共引文献622

同被引文献64

  • 1唐小慧.吉非替尼对晚期肺癌患者的疗效及对血清中胰岛素样生长因子-1、胰岛素样生长因子结合蛋白-3和-7的影响[J].中国老年学杂志,2014,34(2):495-496. 被引量:11
  • 2周清华,孙燕.加强我国肺癌分子靶向治疗基础和临床研究[J].中国肺癌杂志,2004,7(4):267-269. 被引量:51
  • 3Guo F, Yu M, Wang J, et al.Smart IR780 theranostic nanocarrier for tumor-specific therapy: hyperthermia-mediated bubble-generating and folate-targeted liposomes[J].ACS App! Mater Interfaces, 2015, 7 ( 37 ) : 20 556-20 567.
  • 4Crombet Ramos T, Rodrfguez P C, Neninger Vinageras E, et al. CIMAvax EGF ( EGF-P64K ) vaccine for the treatment of non- small-cell lung cancer[J].Expert Rev Vaccines, 2015, 14 ( 10 ) : 1303-1311.
  • 5Ikeuchi M, Ando M, Hisano K, et al.Stent graft for rapidly growing thoracic mycotic aneurysm in a patient with advanced lung cancer[J].Fukuoka Igaku Zasshi, 2015, 106 ( 2 ) : 41-46.
  • 6Kang E J, Min K H, Hur G Y, et al.Comparison of the efficacy between Pemetrexed plus Platinum and non-Pemetrexed plus Platinum as first-line treatment in patients with wild-type epidermal growth factor receptor nonsquamous non-small cell lung cancer: a retrospective analysis[J].Chemotherapy, 2015, 61 ( 1 ) : 41-50.
  • 7Pirker R, Pereira J R, Szczesna A, et al.Cetuximab plus chemotherapy in patients with advanced non-small-cell lungcancer ( FLEX ) : an open-label randomized phased Ill trial[J]. Lancet, 2009, 373 (9674) : 1525-1531.
  • 8Curran W J, Paulus R, Langer C J, et al.Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: Randomized phase III trial RTOG 9410[J].J Natl Cancer Inst, 2011, 103 (19) : 1452-1460.
  • 9Cappuzzo F, Ciuleanu T, Stelmakhl, et al.Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicenter, randomized, p|acebo-controlled phase 3 study[J]. Lancet Oncol, 2010, 11 (6) : $21-529.
  • 10蒋勤娟,王达飞,陈胜东,朱国民.三维适形放射治疗腹腔淋巴结转移癌23例临床观察[J].中国现代医生,2009,47(27):49-50. 被引量:6

引证文献4

二级引证文献7

;
使用帮助 返回顶部